Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer
Drug guidance

Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer

Condition

Cancer

Urological

16 September 2025

-

Published on 16 Sep 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended talazoparib in combination with enzalutamide for inclusion on the MOH List of Subsidised Drugs for treating homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. The decision was based on the low clinical need, uncertain or unfavourable cost-effectiveness compared with treatment alternatives, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for talazoparib plus enzalutamide are provided in the Annex.

Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer (Published 16 Sep 2025) [PDF, 234 KB]

PES Talazoparib in combination with enzalutamide for treating homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer (Published 16 Sep 2025) [PDF, 110 KB]

Back to top